BMS and Infinity trial immunotherapy combo in bladder cancer
No review for three years after final guidance
Cancer Drugs Fund could cover costs in first line use.
Imfinzi given Breakthrough Therapy designation from the FDA.
Contrasting fortunes for Roche and AZ in a week of drama.